Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;102(4):975-980.
doi: 10.1177/13872877241293812. Epub 2024 Nov 25.

Blood-brain barrier permeable β-blockers association with Alzheimer's disease cerebrospinal fluid biomarkers levels in non-demented individuals

Mariateresa Buongiorno  1   2 , Gonzalo Sánchez-Benavides  3   4   5 , Clara Marzal-Espí  6 , Darly Milena Giraldo  1   2 , Jerzy Krupinski  6   7   8 , Natalia Cullell  7 , Oriol Grau-Rivera  3   4   5   9 , Marc Suárez-Calvet  3   4   5   9 , Juan Domingo Gispert  3   4   10 , Alex de la Sierra  7   11 ; Alzheimer's Disease Neuroimaging Initiative **; and the European Prevention of Alzheimer's Disease (EPAD) Consortium
Affiliations

Blood-brain barrier permeable β-blockers association with Alzheimer's disease cerebrospinal fluid biomarkers levels in non-demented individuals

Mariateresa Buongiorno et al. J Alzheimers Dis. 2024 Dec.

Abstract

β-blockers that easily cross the blood-brain barrier (BBB) seem to diminish the risk of Alzheimer's disease (AD), hypothetically facilitating waste clearance. However, their effect on AD pathophysiological markers is unknown. We compared cerebrospinal fluid (CSF) AD biomarker levels among non-demented individuals taking low, intermediate, or high BBB permeable β-blockers in two samples (ADNI: n = 216; EPAD: n = 79). We found that CSF amyloid-β levels were higher in individuals taking highly permeable β-blockers in the ADNI sample. This result was not replicated in EPAD, in which diminished levels of pTau181 and tTau were observed. These data suggest that β-blockers may impact AD pathophysiology.

Keywords: Alzheimer's disease; amyloid-β; beta-blockers; blood-brain barrier; cerebrospinal fluid biomarkers; tau.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article Gonzalo Sánchez-Benavides worked as a consultant for Roche Farma, S.A. Marc Suárez-Calvet has served as a consultant and at advisory boards for Roche Diagnostics International Ltd and has given lectures in symposia sponsored by Roche Diagnostics, S.L.U, Roche Farma, S.A and Roche Sistemas de Diagnosticos, Sociedade Unipessoal, Lda.Gonzalo Sánchez-Benavides is Editorial Board Member of this journal but was not involved in the peer-review process nor had access to any information regarding its peer-review. All other authors have no conflict of interest to report.

LinkOut - more resources